- Company
- Reimb for orphan drug 'Welireg' for cancer has been denied
- by Eo, Yun-Ho Sep 19, 2024 05:48am
- An orphan drug, 'Welireg,' for cancer still faces challenges in entering insurance reimbursement coverage. Sources said that MSD Korea is preparing to reapply for reimbursement review of its oral hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, Welireg (belzutifan), after failing to pass the Cancer Disease Review Committee (CDRC) rev
- Opinion
- [Reporter’s View] Benefits of the U.S. Biosecure Act
- by Son, Hyung Min Sep 13, 2024 05:50am
- The US House of Representatives recently passed the Biosecure Act, which includes the US’s biological sanctions against China. The bill will now head to the US Senate for voting and go through a presidential review process for legislation. The Biosecure Act restricts transactions with major Chinese biotech companies that the U.S. Congres
- Company
- JAK inhibitor 'Jyseleca' approved for use at 'Big 5'
- by Eo, Yun-Ho Sep 13, 2024 05:50am
- The JAK inhibitor 'Jyseleca' has been successfully introduced to general hospitals. Sources said Jyseleca, the fifth JAK inhibitor in South Korea, has passed the drug committees (DC) of 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Sincho
- Policy
- Moderna’s COVID-19 vaccine is approved in Korea
- by Lee, Hye-Kyung Sep 13, 2024 05:50am
- A new COVID-19 variant vaccine, which is the only mRNA-based COVID-19 vaccine that will be manufactured domestically (by Samsung Biologics) has been approved in Korea. The Ministry of Food and Drug Safety (MFDS, Minister: Yu-Kyoung&160;Oh) announced on the 11th that it has authorized the manufacturing and sale of ‘Spikevax JN.1’ that M
- InterView
- ‘Era of once-weekly growth hormones…adherence is key’
- by Hwang, Byung-woo Sep 13, 2024 05:49am
- "The frequency of drug administration is an important factor in the treatment of growth hormone deficiency. The emergence of a once-weekly dosing option is significant in terms of treatment adherence.’ With the market for growth hormone injections rising rapidly, the diversified treatment options have been increasing market interest. The
- Company
- Global guidelines recommend Leclaza combination therapy
- by Son, Hyung-Min Sep 13, 2024 05:49am
- Leclaza plus Rybrevant combination therapy has been listed as a first-line therapy in global guidelines after demonstrating improvements in survival rates. Leclaza plus Rybrevant combination therapy, which is the new treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), received U.S. Food and Drug A
- Company
- Hugel offers guide to safe injection of dermal fillers
- by 어윤호 Sep 12, 2024 04:16pm
- Hugel Inc., a leading global medical aesthetics company, said on Thursday it hosted The Chaeum Safe-tech Session (TSS) seminar for injection of dermal fillers for some 20 medical experts in Seoul on September 11 to improve their understanding of safe treatment and Hugel’s hyaluronic acid filler brand The Chaeum. The lecture covered anatom
- Company
- Yuhan earns ₩80B milestone with Leclaza's FDA nod
- by Chon, Seung-Hyun Sep 12, 2024 05:51am
- On the 11th, Yuhan Corp announced that it will receive USD 60 million (approximately KRW 80 billion) as milestone payments from Janssen Biotech for Leclaza. The company explained, “This is a milestone payment (step-by-step technical fee) for the commercialization of Leclaza and Janssen Biotech's amivantamab combination therapy.” The
- Company
- HK inno.N signs supply deal with Pfizer for COVID-19 vaccine
- by Son, Hyung-Min Sep 12, 2024 05:51am
- HK inno.N announced on September 11th that it has signed an agreement with Pfizer Korea for the domestic distribution of the new COVID-19 vaccine. On September 10th, two companies held an agreement ceremony celebrating the strategic collaboration for the distribution of Pfizer Korea's COVID-19 vaccine, 'Comirnaty JN.1 Inj (bretovameran),
- Company
- Celltrion aims for KRW 5T sales with 'ADC‧CDMO'
- by Hwang, Byung-woo Sep 12, 2024 05:51am
- Celltrion aims to achieve KRW 5 trillion in sales by 2025 based on the growth of the biosimilar pipeline and new business operations. Celltrip Group President Seo Jung-jin and Celltrion CEO Seo Jin-seok announced on September 9th that they have participated in the 'Morgan Stanley 22nd Annual Global Healthcare Conference' in the United St
